Search results
Results from the WOW.Com Content Network
Since the first description of cryoglobulinemia in association with the clinical triad of skin purpura, joint pain, and weakness by Meltzer et al. in 1966, [4] [5] the percentage of cryoglobulinemic diseases described as essential cryoglobulinemia or idiopathic cryoglobulinemia (that is, cryoglobulinemic disease that is unassociated with an underlying disorder) has fallen.
Cold sensitive antibodies (CSA) are antibodies sensitive to cold temperature. Some cold sensitive antibodies are pathological and can lead to blood disorder.These pathological cold sensitive antibodies include cold agglutinins, Donath–Landsteiner antibodies, and cryoglobulins which are the culprits of cold agglutinin disease, paroxysmal cold hemoglobinuria in the process of Donath ...
Rheumatoid factor, cryoglobulins, direct antiglobulin test, and cold agglutinin titer results can be positive. Beta-2 microglobulin and C-reactive protein test results are not specific for Waldenström macroglobulinemia. Beta-2 microglobulin is elevated in proportion to tumor mass.
Cryoglobulinemic vasculitis is a form of inflammation affecting the blood vessels caused by the deposition of abnormal proteins called cryoglobulins.These immunoglobulin proteins are soluble at normal body temperatures, but become insoluble below 37 °C (98.6 °F) and subsequently may aggregate within smaller blood vessels.
A person may also be physically examined for spleen or liver enlargement. An antiglobulin test (called the Coombs test) may be performed to determine the presence of a specific type of antibody. In people with cold agglutinin disease, the Coombs test is almost always positive for immunoglobulin M . [4] [16]
Reflect the stage of cancer; By determining the stage of cancer, it's possible to give a prognosis and treatment plan. [3] Screening for cancers; No screening test is wholly specific, and a high level of tumor marker can still be found in benign tumors. The only tumor marker currently used in screening is PSA (prostate-specific antigen ...
False positive COVID-19 tests—when your result is positive, but you aren’t actually infected with the SARS-CoV-2 virus—are a real, if unlikely, possibility, especially if you don’t perform ...
If the cancer screening does not change the treatment outcome, the screening only prolongs the time the individual lived with the knowledge of their cancer diagnosis. This phenomenon is called lead-time bias. [14] A useful screening program reduces the number of years of potential life lost and disability-adjusted life years lost. However ...